Chicken blastodermal cells (BCs) from stage X embryos produce both somatic and germline chimeras when injected into the subgerminal cavity of recipient embryos. Transfection of the donor cells in vitro could lead to the production of chimeras capable of transmitting the transgene to their offspring. The aim of this study was to transfer and express foreign genes under control of the ovalbumin promoter in the BCs. The results showed that luciferase activity in the BCs reached a plateau value with a 2.0:1.0 or 5.0:1.0 liposome ? DNA ratio and using 1mug of DNA. Under this same condition, no difference was found in relative activity between the pGL-control and pOVALUC plasmid. The expression of other exogenous genes (green fluorescent protein and interferon alpha2a) driven by the chicken ovalbumin promoter in cultured chicken blastodermal cells in vitro is possible by this assay. Hatchability of recipient embryos after injection of 1, 500 or 800 transfected BCs was compared. The advantage of using a smaller number (800) of injected transfected BCs was that early embryonic mortality was reduced and resulted in higher (P<0.01) hatchability (24.5%) than in the case of 1, 500 BCs injected.
The establishment of cancer in a host involves at least two major events: the escape of tumor cells from normal growth control and their escape from immunological recognition. Because of this nature of their development, cancer cells seem to be predominatly poorly immunogenic. In contrast to the previous idea that cancer cells express no recognizable antigens, recent progress in the identification and characterization of tumor antigens, as well as the expansion of knowledge on the cellular and molecular mechanisms of antigen recognition by the immune system, have raised the possibility of using immunotherapy to treat certain tumors. Information on these mechanisms has been obtained in three crucial areas: 1) the role of cytokines in the regulation of the immune response, 2) the molecular characterization of tumor antigens in both mouse and human tumors, and 3) the molecular mechanisms of T cell activation and antigen presentation. Such information has provided new insight into tumor immunology and immunotherapy. Furthermore, recombinant DNA technology allows for modification of the genome of mammalian cells for therapeutic purposes in several diseases. Several novel strategies have been developed to derive genetically modified tumor cells and use them as cellular vaccines to induce antitumor immunity in animal tumor models. This combined modality of genetically modified tumor cells and immunotherapy has been termed immunogene therapy of tumors. Crucial to this approach has been the ability to transfer into normal or neoplastic cells genes known to increase the immunogenicity of cells, which subsequently can be used to augment immune reactions in tumor-bearing mice or cancer patients. While there has been success in inducing antitumor immunity in some tumor models, there are difficulties and limitations in the application of these gene-modified tumor cells for the treatment of preexisting tumors. In this review, recent progress in cancer immunogene therapy is discussed.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.